FASN and breast carcinoma: Further, in breast cancer, knocking down FASN dramatically lowered (by >100 fold) the amount of oestradiol needed to activate ER transcriptional activity, and pharmacologically inhibiting FASN in ER-negative breast cancer cells, stably transfected with ER, increased oestradiol-induced ER-mediated transcriptional activity [124].